MaxCytevsUnitedHealth

MXCT and UNH stock compared: price, dividend, valuation and results, from SEC filings.

MXCT

MaxCyte, Inc.

$1.19

Value $127M

+0.00%
MXCT's page

UNH

UnitedHealth Group Incorporated

$407.46

Value $370B

+0.58%
UNH's page

MaxCyte (MXCT) has a market value of $127M and UnitedHealth (UNH) $370B. Over the last year, with dividends, MXCT moved -24.7% and UNH +23.4%. Dividend yield: MXCT none, UNH 2.22%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MXCT$127M

    UNH$370B

    UNH is 2,908 times MXCT

  • Revenue, 12 months

    MXCT$34M

    UNH$450B

    UNH is 13,081 times MXCT

  • Net income, 12 months

    MXCT-$28M

    UNH$15.9B

  • Operating margin

    MXCT-98.0%

    UNH5.3%

    103.3 points apart

  • ROIC

    MXCT-16.0%

    UNH11.3%

    27.3 points apart

  • P/E

    MXCT–

    UNH23.3

  • Dividend yield

    MXCT0.0%

    UNH2.2%

    2.2 points apart

  • 5-year return

    MXCT-90.5%

    UNH-2.8%

    87.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MXCT-90.5%

UNH-2.8%

05010020222023202420252026
Returns by period
PeriodMXCTWith dividendsUNHWith dividends
1 year since November 12, 2025-24.7%Price -24.7%+23.4%Price +20.2%
3 years since November 13, 2023-65.8%-30.1% a yearPrice -65.8%-20.0%-7.2% a yearPrice -24.9%
5 years since November 12, 2021-90.5%-37.6% a yearPrice -90.5%-2.8%-0.6% a yearPrice -11.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MXCTMaxCyteUNHUnitedHealth

Valuation

MXCTUNH
Valuation
Price$1.19$407.46
Market value$127M$370B
Enterprise value (EV)$26M$416B
P/E–23.3
P/E, 5-year median–25.0
P/B0.83.6
EV/EBIT–17.4
Free cash flow yield–6.2%

Results and growth

MXCTUNH
Results and growth
Revenue, 12 months$34M$450B
Net income, 12 months-$28M$15.9B
Free cash flow, 12 months-$21M$22.8B
Earnings per share, 12 months-$0.26$17.52
Revenue growth, year on year-14.5%11.8%
Revenue growth a year, past+4.8%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

MXCTUNH
Margins and returns on capital
Gross margin81.0%88.3%
Operating margin-98.0%5.3%
Net margin-81.4%3.5%
ROIC-16.0%11.3%
ROE-16.9%15.5%

Balance sheet

MXCTUNH
Balance sheet
Cash$101M$28.5B
Total debt$17M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

MXCTUNH
Dividends and buybacks
Dividend yield–2.2%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.5%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MXCT or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, MaxCyte or UnitedHealth?

By market value, UnitedHealth ($370B) is about 2,908.4 times MaxCyte ($127M), at today's prices.

How did MXCT and UNH stock do over the last 5 years?

Since November 12, 2021, MXCT's price moved -90.5% and UNH's -11.2%. With dividends: MXCT -90.5% (-37.6% a year), UNH -2.8% (-0.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, MXCT or UNH?

The dividend yield at today's price is none for MaxCyte and 2.22% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, MaxCyte or UnitedHealth?

Over the last twelve months, the net margin was -81.4% for MaxCyte and 3.5% for UnitedHealth, and the operating margin -98.0% and 5.3%. Revenue was $34M and $450B.

Which is the better investment, MaxCyte or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.